Clinicopathological and protein characterization of BRAF‐ and K‐RAS‐mutated colorectal cancer and implications for prognosis
Open Access
- 11 November 2009
- journal article
- research article
- Published by Wiley in International Journal of Cancer
- Vol. 127 (2), 367-380
- https://doi.org/10.1002/ijc.25042
Abstract
Recent evidence highlights the potential prognostic and predictive value of BRAF and K‐RAS gene alterations in patients with colorectal cancer. However, a comprehensive evaluation of BRAF and K‐RAS mutations and their specific clinicopathological features, histomorphological presentation and effect on protein expression have not been systematically analyzed. The aim of this study was to characterize the clinicopathological, histomorphological and protein expression profiles of BRAF‐ and K‐RAS‐mutated colorectal cancers and determine their impact on patient survival. Molecular analysis for microsatellite instability (MSI), K‐RAS and BRAF was carried out on paraffin‐embedded samples from 404 patients with primary colorectal cancer. Using tissue microarrays, 36 tumor‐associated and 14 lymphocyte/inflammatory‐associated markers were evaluated by immunohistochemistry. BRAF mutation was associated with right‐sided tumor location (p < 0.001), higher tumor grade (p = 0.029), absence of peritumoral lymphocytic inflammation (p = 0.026) and MSI‐H (p < 0.001). In right‐sided tumors, loss of CDX2 expression was observed in 23 of 24 cases (95.8%). BRAF mutation was a poor prognostic indicator in patients with right‐sided disease (p = 0.01). This result was maintained in multivariable analysis (p < 0.001; HR = 2.82; 95% CI: 1.5–5.5) with pT, pN and vascular invasion and independent of CDX2 expression. K‐RAS mutation, in contrast, was not associated with any of the features analyzed. BRAF gene mutation is an adverse prognostic factor in right‐sided colon cancer patients independent of MSI status and, moreover, in patients with lymph node‐negative disease. These results indicate that molecular analysis for BRAF may be a useful biomarker for identifying patients with right‐sided colon cancer with poor outcome who may benefit from a more individualized course of therapy.Keywords
This publication has 38 references indexed in Scilit:
- BRAFMutation in Metastatic Colorectal CancerThe New England Journal of Medicine, 2009
- Wild-Type BRAF Is Required for Response to Panitumumab or Cetuximab in Metastatic Colorectal CancerJournal of Clinical Oncology, 2008
- CpG island methylator phenotype, microsatellite instability, BRAF mutation and clinical outcome in colon cancerGut, 2008
- RAS Signaling in Colorectal Carcinomas through Alteration of RAS, RAF, NF1, and/or RASSF1ANeoplasia, 2008
- Prognostic Significance of Defective Mismatch Repair and BRAF V600E in Patients with Colon CancerClinical Cancer Research, 2008
- Clinicopathologic Characteristics, CpG Island Methylator Phenotype, and BRAF Mutations in Microsatellite-Stable Colorectal Cancers Without Chromosomal InstabilityArchives of Pathology & Laboratory Medicine, 2008
- Classification of colorectal cancer based on correlation of clinical, morphological and molecular featuresHistopathology, 2006
- The MAPK signalling pathways and colorectal cancerThe Lancet Oncology, 2005
- Kirsten ras Mutations in Patients With Colorectal Cancer: the Multicenter "RASCAL" StudyJNCI Journal of the National Cancer Institute, 1998
- Genetic Alterations during Colorectal-Tumor DevelopmentThe New England Journal of Medicine, 1988